Sharon Yeatts to Deferoxamine
This is a "connection" page, showing publications Sharon Yeatts has written about Deferoxamine.
Connection Strength
0.804
-
Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial. Stroke. 2022 07; 53(7):2204-2210.
Score: 0.198
-
Effect of Deferoxamine on Outcome According to Baseline Hematoma Volume: A Post Hoc Analysis of the i-DEF Trial. Stroke. 2022 04; 53(4):1149-1156.
Score: 0.194
-
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2019 05; 18(5):428-438.
Score: 0.161
-
High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocrit Care. 2013 Oct; 19(2):257-66.
Score: 0.110
-
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke. 2011 Nov; 42(11):3067-74.
Score: 0.095
-
Why Are Women Less Represented in Intracerebral Hemorrhage Trials? Stroke. 2021 01; 52(2):442-446.
Score: 0.046